The Microbiome Therapeutic Market to Grow Through Digital Twin Technology

The Microbiome Therapeutic Market is expected to climb up the ladder of persistence in the next decade. With various healthcare apps on the anvil, there are also mindfulness apps being tabled. They fall in the category of "Wellness apps". With the world wishing for the post-Covid era to function smoothly, these wellness apps are expected to take the healthcare vertical by storm further.

According to the latest market report published by Persistence Market Research, titled 'Microbiome Therapeutics Market Potential: Global Pipeline Analysis and Assessment 2018 - 2025', the global microbiome therapeutics market is expected to exhibit an exponential CAGR of 62.9% during the forecast period 2018-2025.

Persistence Market Research estimates that the global market for microbiome therapeutics is expected to be valued at US$ 10.1 Mn in 2018 and is expected to reach US$ 897.3 Mn by 2025 end. Need for reliable, precise and fast treatment options for certain diseases, such as C. difficile infection (CDI), hepatic encephalopathy and multidrug resistant urinary tract infection creates a huge potential for the growth of the microbiome therapeutics market.

Breakthrough therapy designation and orphan drug approvals for microbiome therapeutics is expected to accelerate the launch of developmental drugs in the microbiome therapeutics market. A huge pipeline with over 120 candidates in different stages of development further creates the platform for potential growth of the microbiome therapeutics market.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/7990

Company Profiles:

Microbiome Therapeutics Inc.
SERES Therapeutics Inc.
LNC Therapeutics Inc.
Vedanta Biosciences Inc.
Enterome SA
Ferring B.V.
ViThera Pharmaceuticals Inc.
Second Genome Therapeutics
Rebiotix
Synlogic Inc.
4D Pharma Plc.
Ritter Pharmaceuticals
AvidBiotics
Osel Inc.
OxThera AB
Evelo Biosciences
AOBiome LLC
Immuron Ltd.

For the entire list of market players, request for Table of Content here @ https://www.persistencemarketresearch.com/market-research/microbiome-therapeutic-market/toc

More Than 120 Drugs Are in the Pipeline in the Global Microbiome Therapeutics Market

At present there are no marketed microbiome therapeutics in the global market; however, the first drug is expected to be launched in 2018. The global market is dominated by over 25 companies with more than 120 drugs in the pipeline at different stages of development.

However, over 60% of these drugs are in the discovery or preclinical phase, where there is high uncertainty surrounding the success of these molecules to reach the clinical phase and being launched as a new drug molecule. Majority of the pipeline drugs are being developed for gastrointestinal disorders and contribute approximately 28.7% of the total pipeline products.

Research and development in the microbiome industry is prominently dependent on government funding and research grants. Formation of policies and provision of subsidy by various governments encourages research and development activities across various segments of the research including discovery and clinical research. Government initiatives in funding microbiome research is the preliminary factor driving revenue growth of global microbiome therapeutics market. For instance, the U.S. government had allocated US$ 1.6 Bn for microbiome R&D programs in 2016 & 2017.

Global Microbiome Therapeutics Market: Segmentation and Forecast

The market is segmented based on indication and region. On the basis of indication, the market has been segmented into type 2 diabetes, obesity, C. difficile infection and primary hyperoxyurea. C. difficile infection indication segment is expected to contribute the highest market share of over 34% by 2025 end. More number of product approvals for CDI is attributed to a high share of the C. difficile infection segment in the global market.

Human gut is home to over 100 Tn bacteria, containing thousands of different species. Long-term exposure to antibiotics causes dysbiosis in gut microbial composition, which leads to a variety of gastrointestinal disorders including CDI, ulcerative colitis, IBD, bacterial infection and even antibiotic associated diarrhea. Microbiome therapeutics however, present an excellent option for the treatment of CDI and other gastrointestinal disorders, as they are designed to naturally cure dysbiosis and bring the microbiome system back to normal functioning.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/7990

Global Microbiome Therapeutics Market: Regional Forecast

On the basis of region, the market has been segmented into the U.S., Europe, Japan and Rest of the World (RoW). U.S. is estimated to contribute the highest share of over 44% by 2025 end, due to early launch of microbiome therapeutics and high penetration compared to other markets. The market in Japan is expected to witness delayed growth due to the complex regulatory pathways for new biological drugs. The microbiome therapeutics market in the rest of the world is expected to show gradual acceptance of "bug medicine", Canada being the most lucrative among the rest of the world countries.

Access Related Reports-

Neuropathic Pain Market: https://www.persistencemarketresearch.com/market-research/neuropathic-pain-market.asp

CAR T-Cell Therapy Market: https://www.persistencemarketresearch.com/market-research/car-t-cell-therapy-market.asp

Contact us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.